Dydyk AM, Jain NK, Gupta M. Opioid Use Disorder [Updated 2022 Jan 28]. Treasure Island, FL: StatPearls Publishing; 2022 [cited 2022 June 13]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK553166/.
Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. Centers for Disease Control and Prevention. Accessed July 26, 2021, at https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm, 2021. Report No.
Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350.
Kelley AT, Incze MA, Baylis JD, et al. Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. Subst Abus. 2022;43(1):1286-99.
van Boekel LC, Brouwers EP, van Weeghel J, et al. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1-2):23-35.
MacDonald K, Lamb K, Thomas ML, et al. Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. Subst Use Misuse. 2016 Jan 2;51(1):85-90.
Kennedy-Hendricks A, Barry CL, Gollust SE, et al. Social Stigma Toward Persons With Prescription Opioid Use Disorder: Associations With Public Support for Punitive and Public Health-Oriented Policies. Psychiatr Serv. 2017;68(5):462-9.
Stone EM, Kennedy-Hendricks A, Barry CL, et al. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627.
Santo T, Jr., Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979-93.
Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139-44.
Snell-Rood C, Willging C, Showalter D, et al. System-level factors shaping the implementation of “hub and spoke” systems to expand MOUD in rural areas. Subst Abus. 2020 7:1-17.
Wakeman SE, Barnett ML. Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities. N Engl J Med. 2018;379(1):1-4.
Melton TC, Hagemeier NE, Tudiver FG, et al. Primary care physicians’ opioid-related prevention behaviors and intentions: A descriptive analysis. J Opioid Manag. 2022;18(1):75-83.
Madras BK, Ahmad NJ, Wen J, et al. Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. NAM Perspect. 2020;2020.
Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275-82.
Lin LA, Knudsen HK. Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States. Ann Fam Med. 2019;17(3):212-20.
Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128-33.
Codell N, Kelley AT, Jones AL, et al. Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities. Am J Drug Alcohol Abuse. 2020 10:1-10.
Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addict Sci Clin Pract. 2012;7:22.
Gordon AJ, Kenny M, Dungan M, et al. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict. 2022;31(2):152-8.
Kelley AT, Dungan MT, Gordon AJ. Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2020 14.
Haffajee RL, Bohnert ASB, Lagisetty PA. Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230-S42.
Oros SM, Christon LM, Barth KS, et al. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. Int J Psychiatry Med. 2021;56(1):14-39.
Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.
Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1-7.
Foti K, Heyward J, Tajanlangit M, et al. Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug Alcohol Depend. 2021;225:108811.
Hawkins EJ, Danner AN, Malte CA, et al. Clinical leaders and providers’ perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs’ facilities. Addict Sci Clin Pract. 2021;16(1):55.
Kilaru AS, Lubitz SF, Davis J, et al. A State Financial Incentive Policy to Improve Emergency Department Treatment for Opioid Use Disorder: A Qualitative Study. Psychiatr Serv. 2021;72(9):1048-56.
Spelman JF, Edens EL, Maya S, et al. A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings. Fed Pract. 2021;38(10):460-4.
Hawkins EJ, Malte CA, Gordon AJ, et al. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA Netw Open. 2021;4(12):e2137238.
Visitor Guide: Spring 2022. In: VA Salt Lake City Health Care System, editor. Salt Lake City, UT: U.S. Department of Veterans Affairs; 2022. p. 1-16.
Richardson DR, Oakes AH, Crossnohere NL, et al. Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling. Psychooncology. 2021;30(7):1104-11.
Crossnohere NL, Janse S, Janssen E, et al. Comparing the Preferences of Patients and the General Public for Treatment Outcomes in Type 2 Diabetes Mellitus. Patient. 2021;14(1):89-100.
Cheung KL, Wijnen BF, Hollin IL, et al. Using Best-Worst Scaling to Investigate Preferences in Health Care. Pharmacoeconomics. 2016;34(12):1195-209.
Whitty JA, Oliveira Goncalves AS. A Systematic Review Comparing the Acceptability, Validity and Concordance of Discrete Choice Experiments and Best-Worst Scaling for Eliciting Preferences in Healthcare. Patient. 2018;11(3):301-17.
Bridges JF, Beusterien K, Heres S, et al. Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling. Patient Prefer Adherence. 2018;12:63-70.
Louviere JJ, Flynn TN, Marley AAJ. Best-worst scaling: Theory, methods and applications: Cambridge University Press; 2015.
Flynn TN, Louviere JJ, Peters TJ, et al. Best--worst scaling: What it can do for health care research and how to do it. J Health Econ. 2007;26(1):171-89.
Hollin IL, Paskett J, Schuster ALR, et al. Best-Worst Scaling and the Prioritization of Objects in Health: A Systematic Review. Pharmacoeconomics. 2022;40(9):883-99.
U.S. Office of Personnel Management (2005). Incentives and Employee Recognition. Accessed June 13, 2022, at https://www.opm.gov/policy-data-oversight/human-capital-framework/reference-materials/talent-management/incentivesrecognition.pdf.
Hauber B, Coulter J. Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications. Appl Health Econ Health Policy. 2020;18(1):31-46.
Hauber B, Mange B, Zhou M, et al. Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM Policy Pract. 2021;6(1):2381468320978407.
Wittenberg E, Bharel M, Bridges JF, et al. Using Best-Worst Scaling to Understand Patient Priorities: A Case Example of Papanicolaou Tests for Homeless Women. Ann Fam Med. 2016;14(4):359-64.
Janssen EM, Benz HL, Tsai JH, et al. Identifying and prioritizing concerns associated with prosthetic devices for use in a benefit-risk assessment: a mixed-methods approach. Expert Rev Med Devices. 2018;15(5):385-98.
Sawtooth Software, Inc. The MaxDiff System Technical Paper. Tchnical Paper Series [Internet]. 2020 June 14, 2022:[1-22 pp.]. Available from: https://sawtoothsoftware.com/resources/technical-papers/maxdiff-technical-paper.
Olson K, Marchalik D, Farley H, et al. Organizational strategies to reduce physician burnout and improve professional fulfillment. Curr Probl Pediatr Adolesc Health Care. 2019;49(12):100664.
Porter J, Boyd C, Skandari MR, et al. Revisiting the Time Needed to Provide Adult Primary Care. J Gen Intern Med. 2022 1.
Nuckols TK, Bhattacharya J, Wolman DM, et al. Cost implications of reduced work hours and workloads for resident physicians. N Engl J Med. 2009;360(21):2202-15.
Sinsky C, Colligan L, Li L, et al. Allocation of Physician Time in Ambulatory Practice: A Time and Motion Study in 4 Specialties. Ann Intern Med. 2016;165(11):753-60.
Clark B, Kai M, Dix R, et al. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders. JAMA Netw Open. 2019;2(10):e1913818.
Zittleman L, Curcija K, Nease DE, Jr., et al. Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices. Ann Fam Med. 2022;20(1):18-23.
Russell HA, Sanders M, Meyer JKV, et al. Increasing Access to Medications for Opioid Use Disorder in Primary Care: Removing the Training Requirement May Not Be Enough. J Am Board Fam Med. 2021;34(6):1212-5.
Terwiesch C, Asch DA, Volpp KG. Technology and Medicine: Reimagining Provider Visits as the New Tertiary Care. Ann Intern Med. 2017;167(11):814-5.
Dela Cruz AM, Walker R, Pipes R, et al. Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. Addict Sci Clin Pract. 2021;16(1):12.
Andrilla CHA, Coulthard C, Larson EH. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder. Ann Fam Med. 2017;15(4):359-62.
Andrilla CHA, Moore TE, Patterson DG. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disor
留言 (0)